Caspofungin - Merck & Co

Drug Profile

Caspofungin - Merck & Co

Alternative Names: Cancidas; Cansidas; Caspofungin acetate; Caspofungin MSD; L 743792; L 743872; MK 0991; MK 991

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antifungals; Echinocandins
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidaemia; Candidiasis; Mycoses

Most Recent Events

  • 03 Oct 2018 Efficacy and safety data from a phase II trial in Candidiasis presented at the IDWeek 2018 (IDW-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 07 Mar 2018 Merck terminates a phase II trial in Candidiasis in USA, Columbia, Bulgaria and Turkey due to operational feasibility following low recruitment due to changing epidemiology of disease (NCT01945281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top